You are here

Article Text

Article menu
Download PDFPDF
Treatment
Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years

https://doi.org/10.1136/ebn.11.2.52

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I Ford

    Dr I Ford, University of Glasgow, Glasgow, UK; ian@stats.gla.ac.uk

    QUESTION

    In middle-aged men with hypercholesterolaemia and no history of myocardial infarction (MI), does 5 years of treatment with pravastatin have long-term benefits for prevention of coronary heart disease (CHD)?

    METHODS

    Design:

    post-trial follow-up of a randomised, placebo-controlled trial (West of Scotland Coronary Prevention Study [WOSCOPS]).

    Allocation:

    unclear allocation concealment.

    Blinding:

    blinded during the trial period {clinicians, patients, data collectors, and outcome adjudication committees}.*

    Follow-up period:

    original trial follow-up was 5 years; this study followed up surviving patients (96%) for 10 more years.

    Setting:

    {coronary screening clinics in the UK}.*

    Patients:

    6595 men {45–64 years of age}* (mean age 55 y) with no history of MI and low-density lipoprotein cholesterol concentrations ⩾155 mg/dl (4.01 mmol/l) on 2 occasions.

    Intervention:

    pravastatin, 40 mg …

    View Full Text

    Footnotes

    • Source of funding: Chief Scientist Office of the Scottish Executive Health Department, Bristol-Myers Squibb, and Sankyo.